Page last updated: 2024-10-18

dalteparin and Exanthema

dalteparin has been researched along with Exanthema in 5 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Exanthema: Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.

Research Excerpts

ExcerptRelevanceReference
" We describe a female patient, whose localized reaction from dalteparin was followed by a generalized rash presenting as acute generalized exanthematous pustulosis."7.74Acute generalized exanthematous pustulosis from dalteparin. ( Aberer, W; Grims, R; Komericki, P; Kränke, B, 2007)
" We describe a female patient, whose localized reaction from dalteparin was followed by a generalized rash presenting as acute generalized exanthematous pustulosis."3.74Acute generalized exanthematous pustulosis from dalteparin. ( Aberer, W; Grims, R; Komericki, P; Kränke, B, 2007)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Righini, M1
Galanaud, JP1
Guenneguez, H1
Brisot, D1
Diard, A1
Faisse, P1
Barrellier, MT1
Hamel-Desnos, C1
Jurus, C1
Pichot, O1
Martin, M1
Mazzolai, L1
Choquenet, C1
Accassat, S1
Robert-Ebadi, H1
Carrier, M1
Le Gal, G1
Mermilllod, B1
Laroche, JP1
Bounameaux, H1
Perrier, A1
Kahn, SR1
Quere, I1
Mattioli, M1
Fustini, E1
Gennarini, S1
Kim, KH1
Lynfield, Y1
Komericki, P1
Grims, R1
Kränke, B1
Aberer, W1
Rupec, RA1
Boneberger, S1
Ruzicka, T1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Contention Alone Versus Anticoagulation for Symptomatic Calf Vein Thrombosis Diagnosed by Ultrasonography[NCT00421538]Phase 3260 participants (Actual)Interventional2008-01-31Completed
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis[NCT04981327]Phase 31,300 participants (Anticipated)Interventional2022-09-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for dalteparin and Exanthema

ArticleYear
[Adverse cutaneous drug reactions].
    Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:50

    Topics: Acneiform Eruptions; Dalteparin; Diagnosis, Differential; Drug Eruptions; Eosinophilia; ErbB Recepto

2007

Trials

1 trial available for dalteparin and Exanthema

ArticleYear
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:12

    Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan

2016
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:12

    Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan

2016
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:12

    Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan

2016
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:12

    Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan

2016

Other Studies

3 other studies available for dalteparin and Exanthema

ArticleYear
Heart transplant recipient patient with COVID-19 treated with tocilizumab.
    Transplant infectious disease : an official journal of the Transplantation Society, 2020, Volume: 22, Issue:6

    Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Cardiomyopathy, Dilated; C

2020
Enoxaparin-induced generalized exanthem.
    Cutis, 2003, Volume: 72, Issue:1

    Topics: Biopsy, Needle; Drug Eruptions; Enoxaparin; Exanthema; Female; Follow-Up Studies; Humans; Immunohist

2003
Acute generalized exanthematous pustulosis from dalteparin.
    Journal of the American Academy of Dermatology, 2007, Volume: 57, Issue:4

    Topics: Acute Disease; Anticoagulants; Dalteparin; Drug Eruptions; Exanthema; Female; Humans; Injections; Mi

2007